Vanguard Group Inc Cytek Biosciences, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,622,008 shares of CTKB stock, worth $26.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,622,008
Previous 11,716,843
17.88%
Holding current value
$26.7 Million
Previous $76 Million
49.26%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CTKB
# of Institutions
160Shares Held
73.8MCall Options Held
600Put Options Held
4.9K-
Black Rock Inc. New York, NY17.1MShares$47.3 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.46MShares$20.7 Million0.93% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$18.4 Million0.82% of portfolio
-
State Street Corp Boston, MA4.38MShares$12.1 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.85MShares$7.91 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $373M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...